This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Syntarga Bv, Byondis B.v., Synthon Biopharmaceuticals B.v.. Active years: 2014-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 10 
1 out of 18 
1 out of 11 Years Active: 2014-2022
Title: Innovations in Drug Delivery: The Contributions of Tijl Huijbregts
Introduction: Tijl Huijbregts, an accomplished inventor based in Nijmegen, Netherlands, has made significant strides in the field of drug delivery systems. With a total of 4 patents to his name, Huijbregts focuses on creating innovative compounds that enhance the effectiveness of cancer treatments. His work exemplifies the intersection of chemistry and medicine, as he develops solutions that aim to improve therapeutic outcomes for patients.
Latest Patents: Among his latest innovations, Huijbregts has pioneered a patent for "Non-linear self-immolative linkers and conjugates thereof". This invention relates to linker-drug compounds and antibody-drug conjugates that feature a non-linear self-immolative linker. This linker is designed to be cleavable or transformable under specific conditions, helping to reduce the hydrophobicity of the resulting conjugate.
Additionally, Huijbregts holds a patent for "Substituted CC-1065 analogs and their conjugates". This invention focuses on novel agents that are analogs of the DNA-alkylating agent CC-1065 and includes their conjugates. These agents and conjugates are intended to target undesired cell proliferation, such as that found in tumors, by releasing their therapeutic payloads selectively and at controlled rates.
Career Highlights: Huijbregts has worked at prominent companies in the pharmaceutical sector, notably Syntarga B.V. and Synthon Biopharmaceuticals B.V. His experience in these organizations has undoubtedly enriched his expertise and contributed to his innovative efforts in drug development.
Collaborations: Throughout his career, Huijbregts has collaborated with various talented individuals, including coworkers Patrick Henry Beusker and Henri Johannes Spijker. These partnerships have facilitated the exchange of ideas and fostered an environment conducive to breakthroughs in pharmaceutical innovations.
Conclusion: Tijl Huijbregts stands out as an influential figure in the realm of pharmaceuticals, with a strong focus on enhancing drug delivery systems through innovative compounds. His patents, achievements, and collaborations underscore his commitment to developing solutions that address critical health challenges, particularly in the treatment of cancer. As his work progresses, it holds the potential to significantly impact the efficacy of cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile